Abstract:BCR-ABL kinase inhibition is an effective strategy for the treatment of chronic myeloid leukemia (CML). Herein, we report compound 3a-P1, bearing a difluoro-indene scaffold, as a novel potent pan-inhibitor against BCR-ABL mutants, including the most refractory T315I mutant. As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively. 3a-P1 displayed a good safety profile in a battery of assays, including single-dose toxicity, hERG K+, and genotoxicity. It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 h·ng/mL). Importantly, 3a-P1 demonstrated a higher potency than ponatinib in a mice xenograft model of BaF3 harboring BCR-ABLT315I. Overall, the results indicate that 3a-P1 is a promising drug candidate for the treatment of CML to overcome the imatinib-resistant T315I BCR-ABL mutation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00082?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00082</a>.Synthesis of compounds 17a–e, crystal data for compound 29, SFC report for compounds 3a and 3b, and the determination of the absolute configuration of compound (S)-23 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00082/suppl_file/jm1c00082_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00082/suppl_file/jm1c00082_si_002.csv">CSV</a>)X-ray crystal structure data for compound 29 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00082/suppl_file/jm1c00082_si_003.cif">CIF</a>)This article has not yet been cited by other publications.

Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl) benzamide derivatives as potent pan Bcr-Abl inhibitors including the threonine315←isoleucine315 mutant

Design, Synthesis, and Biological Evaluation of Novel Bcr-AblT315I Inhibitors Incorporating Amino Acids As Flexible Linker

Design, Synthesis, and Biological Evaluation of Trizole-Based Heteroaromatic Derivatives As Bcr-Abl Kinase Inhibitors.

Discovery of a Candidate Containing an ( S )-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1 H -inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia

Integrating amino acids into Bcr-Abl inhibitors: design, synthesis, biological evaluation, and in silico studies

Hybrid Pyrimidine Alkynyls Inhibit The Clinically Resistance Related Bcr-Abl(T315i) Mutant

Discovery of Novel Bcr-AblT315I Inhibitors with Flexible Linker. Part 1: Confirmation Optimization of Phenyl-1H-indazol-3-amine As Hinge Binding Moiety.

Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors.

Discovery of a Candidate Containing an (S)-3,3-difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1h-inden Scaffold As a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation

Biological Evaluation of 2-Methylpyrimidine Derivatives As Active Pan Bcr-Abl Inhibitors

Design, Synthesis, and Biological Evaluation of Novel Water-Soluble Triptolide Derivatives: Antineoplastic Activity Against Imatinib-Resistant CML Cells Bearing T315I Mutant Bcr-Abl

Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1 H -indazol-3-amine

Design, Synthesis, and Biological Evaluation of Bcr-Abl PROTACs to Overcome T315I Mutation

Identification of Gzd824 As an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance Against Imatinib

Discovery of Novel Bcr–Abl Inhibitors Targeting Myristoyl Pocket and ATP Site

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Synthesis and Biological Evaluation of Novel Aromatic-Heterocyclic Biphenyls As Potent Anti-Leukemia Agents

Recent Advances In Bcr-Abl Tyrosine Kinase Inhibitors For Overriding T315i Mutation

Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl T315I inhibitor overcoming acquired imatinib resistance.